source
- Cerevance's solengepras cuts OFF time in phase 3 Parkinson's trialCerevance reported that its oral non‑dopaminergic therapy, solengepras, produced meaningful improvements in both motor and non‑motor symptoms in a phase 3 Parkinson's disease study, rescuing the ca…
- Cadrenal Therapeutics launches strategic review to explore sale or partnership for its late-stage cardiology pipelineCadrenal Therapeutics, a heart-focused biotech, announced a strategic review of its late-stage cardiology pipeline, seeking to offload assets or the entire company. The board is evaluating options…